APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetic COPD

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Genetic COPD Industry Growth and Trends Forecast to 2032

2 January 2026120 pages

Choose your research edition.

Industry ResearchGenetic COPD Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic COPD Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Genetic COPD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic COPD Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic COPD Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

According to APO Research, the global Genetic COPD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Genetic COPD is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Genetic COPD is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetic COPD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Genetic COPD market include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Genetic COPD market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Genetic COPD market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Genetic COPD market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Genetic COPD.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Genetic COPD market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Genetic COPD Market by Company

Takeda

Pfizer

GlaxoSmithKline

Baxter

AstraZeneca

Vertex Pharmaceuticals

Teva Pharmaceutical Industries

ProMetic Life Sciences

ProBioGen

LFB Biomedicaments

Kedrion Group

Kamada Ltd

Grifols

CSL Behring

Chiesi Pharmaceuticals

Boehringer Ingelheim

Biogen

Baxalta

Arrowhead Research Corporation

Abeona Therapeutics

Genetic COPD Segment by Type

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Other

Genetic COPD Segment by Application

Specialty Clinics

Hospitals

Pharmacies

Others

Genetic COPD Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic COPD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Genetic COPD companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Genetic COPD Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Genetic COPD Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Genetic COPD Market Share by Region (2021-2026) Table 4. Global Genetic COPD Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Genetic COPD Market Share by Region (2027-2032) Table 6. Global Genetic COPD Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Genetic COPD Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Genetic COPD Market Size Share by Type (2021-2026) Table 9. Global Genetic COPD Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Genetic COPD Market Size Share Forecasted by Type (2027-2032) Table 11. North America Genetic COPD Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Genetic COPD Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Genetic COPD Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Genetic COPD Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Genetic COPD Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Genetic COPD Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Genetic COPD Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Genetic COPD Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Genetic COPD Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Genetic COPD Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Genetic COPD Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Genetic COPD Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Genetic COPD Market Size Share by Application (2021-2026) Table 24. Global Genetic COPD Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Genetic COPD Market Size Share Forecasted by Application (2027-2032) Table 26. North America Genetic COPD Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Genetic COPD Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Genetic COPD Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Genetic COPD Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Genetic COPD Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Genetic COPD Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Genetic COPD Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Genetic COPD Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Genetic COPD Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Genetic COPD Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Genetic COPD Industry Trends Table 37. Genetic COPD Industry Drivers Table 38. Genetic COPD Industry Opportunities and Challenges Table 39. Genetic COPD Industry Restraints Table 40. Global Genetic COPD Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Genetic COPD Revenue Market Share by Company (2021-2026) Table 42. Global Genetic COPD Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Genetic COPD Key Company Headquarters & Area Served Table 44. Global Genetic COPD Company, Product Type & Application Table 45. Global Genetic COPD Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Genetic COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Takeda Company Information Table 49. Takeda Business Overview Table 50. Takeda Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Takeda Genetic COPD Product Portfolio Table 52. Takeda Recent Development Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Pfizer Genetic COPD Product Portfolio Table 57. Pfizer Recent Development Table 58. GlaxoSmithKline Company Information Table 59. GlaxoSmithKline Business Overview Table 60. GlaxoSmithKline Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline Genetic COPD Product Portfolio Table 62. GlaxoSmithKline Recent Development Table 63. Baxter Company Information Table 64. Baxter Business Overview Table 65. Baxter Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Baxter Genetic COPD Product Portfolio Table 67. Baxter Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AstraZeneca Genetic COPD Product Portfolio Table 72. AstraZeneca Recent Development Table 73. Vertex Pharmaceuticals Company Information Table 74. Vertex Pharmaceuticals Business Overview Table 75. Vertex Pharmaceuticals Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Vertex Pharmaceuticals Genetic COPD Product Portfolio Table 77. Vertex Pharmaceuticals Recent Development Table 78. Teva Pharmaceutical Industries Company Information Table 79. Teva Pharmaceutical Industries Business Overview Table 80. Teva Pharmaceutical Industries Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Teva Pharmaceutical Industries Genetic COPD Product Portfolio Table 82. Teva Pharmaceutical Industries Recent Development Table 83. ProMetic Life Sciences Company Information Table 84. ProMetic Life Sciences Business Overview Table 85. ProMetic Life Sciences Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. ProMetic Life Sciences Genetic COPD Product Portfolio Table 87. ProMetic Life Sciences Recent Development Table 88. ProBioGen Company Information Table 89. ProBioGen Business Overview Table 90. ProBioGen Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. ProBioGen Genetic COPD Product Portfolio Table 92. ProBioGen Recent Development Table 93. LFB Biomedicaments Company Information Table 94. LFB Biomedicaments Business Overview Table 95. LFB Biomedicaments Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. LFB Biomedicaments Genetic COPD Product Portfolio Table 97. LFB Biomedicaments Recent Development Table 98. Kedrion Group Company Information Table 99. Kedrion Group Business Overview Table 100. Kedrion Group Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Kedrion Group Genetic COPD Product Portfolio Table 102. Kedrion Group Recent Development Table 103. Kamada Ltd Company Information Table 104. Kamada Ltd Business Overview Table 105. Kamada Ltd Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Kamada Ltd Genetic COPD Product Portfolio Table 107. Kamada Ltd Recent Development Table 108. Grifols Company Information Table 109. Grifols Business Overview Table 110. Grifols Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Grifols Genetic COPD Product Portfolio Table 112. Grifols Recent Development Table 113. CSL Behring Company Information Table 114. CSL Behring Business Overview Table 115. CSL Behring Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. CSL Behring Genetic COPD Product Portfolio Table 117. CSL Behring Recent Development Table 118. Chiesi Pharmaceuticals Company Information Table 119. Chiesi Pharmaceuticals Business Overview Table 120. Chiesi Pharmaceuticals Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Chiesi Pharmaceuticals Genetic COPD Product Portfolio Table 122. Chiesi Pharmaceuticals Recent Development Table 123. Boehringer Ingelheim Company Information Table 124. Boehringer Ingelheim Business Overview Table 125. Boehringer Ingelheim Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Boehringer Ingelheim Genetic COPD Product Portfolio Table 127. Boehringer Ingelheim Recent Development Table 128. Biogen Company Information Table 129. Biogen Business Overview Table 130. Biogen Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Biogen Genetic COPD Product Portfolio Table 132. Biogen Recent Development Table 133. Baxalta Company Information Table 134. Baxalta Business Overview Table 135. Baxalta Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Baxalta Genetic COPD Product Portfolio Table 137. Baxalta Recent Development Table 138. Arrowhead Research Corporation Company Information Table 139. Arrowhead Research Corporation Business Overview Table 140. Arrowhead Research Corporation Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Arrowhead Research Corporation Genetic COPD Product Portfolio Table 142. Arrowhead Research Corporation Recent Development Table 143. Abeona Therapeutics Company Information Table 144. Abeona Therapeutics Business Overview Table 145. Abeona Therapeutics Genetic COPD Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Abeona Therapeutics Genetic COPD Product Portfolio Table 147. Abeona Therapeutics Recent Development Table 148. North America Genetic COPD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Genetic COPD Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Genetic COPD Market Share by Country (2021-2026) Table 151. North America Genetic COPD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Genetic COPD Market Share Forecast by Country (2027-2032) Table 153. Europe Genetic COPD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Genetic COPD Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Genetic COPD Market Share by Country (2021-2026) Table 156. Europe Genetic COPD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Genetic COPD Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Genetic COPD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Genetic COPD Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Genetic COPD Market Share by Country (2021-2026) Table 161. Asia-Pacific Genetic COPD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Genetic COPD Market Share Forecast by Country (2027-2032) Table 163. Latin America Genetic COPD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Genetic COPD Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Genetic COPD Market Share by Country (2021-2026) Table 166. Latin America Genetic COPD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Genetic COPD Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Genetic COPD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Genetic COPD Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Genetic COPD Market Share by Country (2021-2026) Table 171. Middle East & Africa Genetic COPD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Genetic COPD Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Genetic COPD Product Image Figure 3. Global Genetic COPD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Genetic COPD Market Size (2021-2032) & (US$ Million) Figure 5. Global Genetic COPD Market Share by Region: 2025 VS 2032 Figure 6. Global Genetic COPD Market Share by Region (2021-2032) Figure 7. North America Genetic COPD Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Genetic COPD Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Genetic COPD Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Genetic COPD Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Genetic COPD Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Augmentation Therapy Image Figure 13. Global Augmentation Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Cystic Fibrosis(CF) Image Figure 15. Global Cystic Fibrosis(CF) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Non-CF Bronchiectasis(NCFB) Image Figure 17. Global Non-CF Bronchiectasis(NCFB) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Other Image Figure 19. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Genetic COPD Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Genetic COPD Market Share by Type 2025 VS 2032 Figure 22. North America Genetic COPD Market Size Share by Type (2021-2032) Figure 23. Europe Genetic COPD Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Genetic COPD Market Size Share by Type (2021-2032) Figure 25. Latin America Genetic COPD Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Genetic COPD Market Size Share by Type (2021-2032) Figure 27. Specialty Clinics Image Figure 28. Global Specialty Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Hospitals Image Figure 30. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Pharmacies Image Figure 32. Global Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Others Image Figure 34. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Genetic COPD Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Genetic COPD Market Share by Application 2025 VS 2032 Figure 37. North America Genetic COPD Market Size Share by Application (2021-2032) Figure 38. Europe Genetic COPD Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Genetic COPD Market Size Share by Application (2021-2032) Figure 40. Latin America Genetic COPD Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Genetic COPD Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Genetic COPD Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Genetic COPD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Genetic COPD Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Genetic COPD Market Share by Country (2021-2032) Figure 47. Europe Genetic COPD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Genetic COPD Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Genetic COPD Market Share by Country (2021-2032) Figure 50. Asia-Pacific Genetic COPD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Genetic COPD Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Genetic COPD Market Share by Country (2021-2032) Figure 53. Latin America Genetic COPD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Genetic COPD Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Genetic COPD Market Share by Country (2021-2032) Figure 56. Middle East & Africa Genetic COPD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Genetic COPD Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Genetic COPD Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Other
Applications
  • Specialty Clinics
  • Hospitals
  • Pharmacies
  • Others
Companies covered
  • Takeda
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Teva Pharmaceutical Industries
  • ProMetic Life Sciences
  • ProBioGen
  • LFB Biomedicaments
  • Kedrion Group
  • Kamada Ltd
  • Grifols
  • CSL Behring
  • Chiesi Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen
  • Baxalta
  • Arrowhead Research Corporation
  • Abeona Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Genetic COPD Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Genetic COPD Market Size by Region (2021-2032)
  5. 1.4.1 Global Genetic COPD Market Size by Region (2021-2026)
  6. 1.4.2 Global Genetic COPD Market Size by Region (2027-2032)
  7. 1.5 Key Regions Genetic COPD Market Size (2021-2032)
  8. 1.5.1 North America Genetic COPD Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Genetic COPD Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Genetic COPD Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Genetic COPD Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Genetic COPD Market Size Growth Rate (2021-2032)
2 Genetic COPD Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Augmentation Therapy
  3. 2.1.2 Cystic Fibrosis(CF)
  4. 2.1.3 Non-CF Bronchiectasis(NCFB)
  5. 2.1.4 Other
  6. 2.2 Global Genetic COPD Market Size by Type
  7. 2.2.1 Global Genetic COPD Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Genetic COPD Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Genetic COPD Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Genetic COPD Market Size by Regions
  11. 2.3.1 North America Genetic COPD Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Genetic COPD Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Genetic COPD Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Genetic COPD Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Genetic COPD Market Size Breakdown by Type (2021-2026)
3 Genetic COPD Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Specialty Clinics
  3. 3.1.2 Hospitals
  4. 3.1.3 Pharmacies
  5. 3.1.4 Others
  6. 3.2 Global Genetic COPD Market Size by Application
  7. 3.2.1 Global Genetic COPD Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Genetic COPD Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Genetic COPD Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Genetic COPD Market Size by Regions
  11. 3.3.1 North America Genetic COPD Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Genetic COPD Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Genetic COPD Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Genetic COPD Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Genetic COPD Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Genetic COPD Industry Trends
  2. 4.2 Genetic COPD Industry Drivers
  3. 4.3 Genetic COPD Industry Opportunities and Challenges
  4. 4.4 Genetic COPD Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Genetic COPD Revenue (2021-2026)
  2. 5.2 Global Genetic COPD Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Genetic COPD Key Company Headquarters & Area Served
  4. 5.4 Global Genetic COPD Company, Product Type & Application
  5. 5.5 Global Genetic COPD Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Genetic COPD Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Genetic COPD Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Genetic COPD Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Genetic COPD Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Genetic COPD Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline Genetic COPD Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Baxter
  20. 6.4.1 Baxter Company Information
  21. 6.4.2 Baxter Business Overview
  22. 6.4.3 Baxter Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Baxter Genetic COPD Product Portfolio
  24. 6.4.5 Baxter Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Genetic COPD Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Vertex Pharmaceuticals
  32. 6.6.1 Vertex Pharmaceuticals Company Information
  33. 6.6.2 Vertex Pharmaceuticals Business Overview
  34. 6.6.3 Vertex Pharmaceuticals Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Vertex Pharmaceuticals Genetic COPD Product Portfolio
  36. 6.6.5 Vertex Pharmaceuticals Recent Developments
  37. 6.7 Teva Pharmaceutical Industries
  38. 6.7.1 Teva Pharmaceutical Industries Company Information
  39. 6.7.2 Teva Pharmaceutical Industries Business Overview
  40. 6.7.3 Teva Pharmaceutical Industries Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Teva Pharmaceutical Industries Genetic COPD Product Portfolio
  42. 6.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 6.8 ProMetic Life Sciences
  44. 6.8.1 ProMetic Life Sciences Company Information
  45. 6.8.2 ProMetic Life Sciences Business Overview
  46. 6.8.3 ProMetic Life Sciences Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 ProMetic Life Sciences Genetic COPD Product Portfolio
  48. 6.8.5 ProMetic Life Sciences Recent Developments
  49. 6.9 ProBioGen
  50. 6.9.1 ProBioGen Company Information
  51. 6.9.2 ProBioGen Business Overview
  52. 6.9.3 ProBioGen Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 ProBioGen Genetic COPD Product Portfolio
  54. 6.9.5 ProBioGen Recent Developments
  55. 6.10 LFB Biomedicaments
  56. 6.10.1 LFB Biomedicaments Company Information
  57. 6.10.2 LFB Biomedicaments Business Overview
  58. 6.10.3 LFB Biomedicaments Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 LFB Biomedicaments Genetic COPD Product Portfolio
  60. 6.10.5 LFB Biomedicaments Recent Developments
  61. 6.11 Kedrion Group
  62. 6.11.1 Kedrion Group Company Information
  63. 6.11.2 Kedrion Group Business Overview
  64. 6.11.3 Kedrion Group Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Kedrion Group Genetic COPD Product Portfolio
  66. 6.11.5 Kedrion Group Recent Developments
  67. 6.12 Kamada Ltd
  68. 6.12.1 Kamada Ltd Company Information
  69. 6.12.2 Kamada Ltd Business Overview
  70. 6.12.3 Kamada Ltd Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Kamada Ltd Genetic COPD Product Portfolio
  72. 6.12.5 Kamada Ltd Recent Developments
  73. 6.13 Grifols
  74. 6.13.1 Grifols Company Information
  75. 6.13.2 Grifols Business Overview
  76. 6.13.3 Grifols Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Grifols Genetic COPD Product Portfolio
  78. 6.13.5 Grifols Recent Developments
  79. 6.14 CSL Behring
  80. 6.14.1 CSL Behring Company Information
  81. 6.14.2 CSL Behring Business Overview
  82. 6.14.3 CSL Behring Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 CSL Behring Genetic COPD Product Portfolio
  84. 6.14.5 CSL Behring Recent Developments
  85. 6.15 Chiesi Pharmaceuticals
  86. 6.15.1 Chiesi Pharmaceuticals Company Information
  87. 6.15.2 Chiesi Pharmaceuticals Business Overview
  88. 6.15.3 Chiesi Pharmaceuticals Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Chiesi Pharmaceuticals Genetic COPD Product Portfolio
  90. 6.15.5 Chiesi Pharmaceuticals Recent Developments
  91. 6.16 Boehringer Ingelheim
  92. 6.16.1 Boehringer Ingelheim Company Information
  93. 6.16.2 Boehringer Ingelheim Business Overview
  94. 6.16.3 Boehringer Ingelheim Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Boehringer Ingelheim Genetic COPD Product Portfolio
  96. 6.16.5 Boehringer Ingelheim Recent Developments
  97. 6.17 Biogen
  98. 6.17.1 Biogen Company Information
  99. 6.17.2 Biogen Business Overview
  100. 6.17.3 Biogen Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Biogen Genetic COPD Product Portfolio
  102. 6.17.5 Biogen Recent Developments
  103. 6.18 Baxalta
  104. 6.18.1 Baxalta Company Information
  105. 6.18.2 Baxalta Business Overview
  106. 6.18.3 Baxalta Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Baxalta Genetic COPD Product Portfolio
  108. 6.18.5 Baxalta Recent Developments
  109. 6.19 Arrowhead Research Corporation
  110. 6.19.1 Arrowhead Research Corporation Company Information
  111. 6.19.2 Arrowhead Research Corporation Business Overview
  112. 6.19.3 Arrowhead Research Corporation Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Arrowhead Research Corporation Genetic COPD Product Portfolio
  114. 6.19.5 Arrowhead Research Corporation Recent Developments
  115. 6.20 Abeona Therapeutics
  116. 6.20.1 Abeona Therapeutics Company Information
  117. 6.20.2 Abeona Therapeutics Business Overview
  118. 6.20.3 Abeona Therapeutics Genetic COPD Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Abeona Therapeutics Genetic COPD Product Portfolio
  120. 6.20.5 Abeona Therapeutics Recent Developments
7 North America
  1. 7.1 North America Genetic COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Genetic COPD Market Size by Country (2021-2026)
  3. 7.3 North America Genetic COPD Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Genetic COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Genetic COPD Market Size by Country (2021-2026)
  3. 8.3 Europe Genetic COPD Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Genetic COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Genetic COPD Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Genetic COPD Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Genetic COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Genetic COPD Market Size by Country (2021-2026)
  3. 10.3 South America Genetic COPD Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Genetic COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Genetic COPD Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Genetic COPD Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst